Regional Healthcare Providers and Partners

Cancer Centre Contact Us



Regional Cancer Programs were created and are funded by Cancer Care Ontario. They respond to local cancer issues. They also coordinate care across local and regional healthcare providers and work to continually improve access to care, wait times and the quality of programs and services.

The Erie St. Clair Regional Cancer Program is responsible for the quality and delivery of cancer services for the areas of Chatham-Kent, Sarnia/Lambton, and Windsor/Essex. It is a network of healthcare professionals and organizations involved in cancer prevention and care. It is overseen by a Regional Vice President of Cancer Services and is supported by staff.

It is one of 14 Regional Cancer Programs across Ontario. For each Regional Cancer Program, there is a regional cancer centre. Windsor Regional Hospital operates the regional cancer centre for Erie St. Clair.

The following links contain additional information about the Regional Cancer Program and Cancer Care Ontario:

Erie St. Clair Regional Cancer Program Partners



Cancer Education Day - September 2019

LHIN 1 GU Retreat 2019



Cancer Screening Programs

Ontario Breast Screening Program (OBSP)

  Average Risk High Risk
Screening Population Women ages 50 to 74 with no acute breast symptoms and no personal history of breast cancer. Women ages 30 to 69 confirmed to be a high risk through the OBSP High-Risk Screening Program
Screening Recommendation Mammogram every two years.

Mammography is the preferred screening method for women at average risk of developing breast cancer.
Mammogram and breast MRI every year.
For Referral Criteria, please see below.
How to Screen/Refer Breast cancer screening is free-of-charge for women in Ontario. Women can contact any of the OBSP locations below for an appointment. Doctor referral is not required. Physicians can refer patients using the OBSP Requisition for High Risk Screening to be assessed by the Genetic Counsellor at Windsor Regional Hospital for eligibility.

Referrals can be faxed to 519-255-8688.

To contact the Genetic Counsellor, call 519-254-5577 ext. 58601.

Referral Criteria

  • A known carrier of a gene mutation (e.g. BRCA 1, BRCA 2).
  • Assessed by a genetic clinic as having a  25% personal lifetime risk of breast cancer.
  • Received chest radiation (not chest x-ray) before age 30 and at least 8 years previously.
  • First degree relative of a carrier of a gene mutation who has not previously has genetic counselling or genetic testing or has previously declined genetic testing.
  • Personal or family history of breast and/or ovarian cancer suggestive of a hereditary breast cancer syndrome.

Ontario Breast Screening Program Guidelines Summary.

Certain patients may be eligible for the High Risk Screening Program. Please see the form in the chart above to assess eligibility and fax completed forms to the OBSP Program as required.

Ontario Cervical Screening Program (OCSP)

ColonCancerCheck (CCC)

  Average Risk Increased Risk Symptomatic*
Screening Population People ages 50 to 74 with no first-degree relatives diagnosed with colorectal cancer and no personal history of pre-cancerous colorectal polyps or inflammatory bowel disease. People with one or more first-degree relatives diagnosed with colorectal cancer, but do not meet the criteria for colorectal cancer hereditary syndrome.
  • Palpable mass
  • Abnormal imaging suggesting CRC

Rectal bleed:
  • With dark rectal bleed
  • Mixed with stool
  • Without obvious cause
  • With a change in bowel habits
  • With weight loss
Unexplained iron-deficiency anemia
(hb < 110 for men and <100 for females not menstruating and iron below normal range)
Screening Recommendation Fecal Immunochemical Test (FIT) every two years. An abnormal FIT should be followed up with a colonoscopy within eight weeks. Colonoscopy beginning at age 50 or 10 years earlier than the age that a first-degree relative was diagnosed with colorectal cancer (whichever occurs first). Colonoscopy within 4 weeks. Colonoscopy within 8 weeks.
How to Screen/Refer Primary care providers can order a FIT kit by completing the new Cancer Care Ontario FIT requisition. People without a primary care provider can get a FIT kit by contacting Telehealth Ontario at 1-866-828-9213.

To order a colonoscopy for an abnormal FIT, complete the new FIT+ Requisition.
A colonoscopy can be arranged through the Diagnostic Assessment Program (DAP) by using the DAP Referral Form.

Referrals can be faxed to 519-255-8688.

A colonoscopy can be arranged through an Endoscopist of your choice by faxing a requisition directly to their office. Click here for a list of Endoscopsits and fax numbers.  

If you are interested in ordering cancer screening resources for your office or your patients, please call 519-254-5577 ext. 58620.

Clinical Trials

A clinical trial is a type of research study that helps to find new ways to diagnose, treat, manage or prevent disease. Clinical trials test new drugs, new ways to do radiation or surgery, or any combination of these.
Clinical trials help us learn about how to make cancer treatment and cancer care better. Most of the treatments prescribed by physicians who went through the clinical trial process at some point; this is how it was determined that they would benefit patients.

In order to conduct clinical trials, investigators must satisfy a number of regulatory requirements and ensure the trial and all its components are approved by a Research Ethics Board.

At WRH, the Cancer Program has a Clinical Trials Department which facilitates meeting these regulatory requirements and also assists in running and managing Clinical Trials. We currently have 5 staff members in the department, four Study Coordinators running the trials and recruiting patients, and one Business Coordinator who manages the day to day and administrative logistics, including study contracts, budgets, training requirements and study startup.

Study Short Name Protocol Title Principal Investigator
TREATER+IGHT Treatment of Canadian Postmenopausal Women with ER+ Advanced Breast Cancer in the Real-World Setting with Hormone Therapy ± Targeted Therapy Dr. Swati Kulkarni
JASMINE 20130109 A randomized, Double-blind Study Evaluating the efficacy, safety, and immunogenicity of ABP 798 compared with Rituximab in subjects with CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL) Dr. Caroline Hamm
PCS VI Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High-Risk Adenocarcinoma of the Prostate Dr. Junaid Yousuf
LUSTRE Medically-inoperative Stage I non-small cell lung cancer comparing stereotactic body radiotherapy vs conventional radiotherapy Dr. Khalid Hirmiz
BMS CA209-451 A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy Dr. Tarek Elfiki
BR.34 A Randomized Trial of Durvalumab (MEDI4736) and Tremelimumab + Platinum-Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Dr. Swati Kulkarni
DIV-SCLC-301 A two-part, open-label, randomized, phase II/III study of dinutuximab and irinotecan vs. irinotecan for second-line treatment of subjects with relapsed or refractory small cell lung cancer Dr. Tarek Elfiki
MERU A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer Dr. Amin Kay
PR.19 A Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer Dr. Colvin Springer
NEPA-001 - NOT YET OPEN A Phase IV, Real World Observational Study on the Use of Akynzeo™ (netupitant/palonosetron) for the Prevention of Nausea and Vomiting in Oncology Patients Receiving Highly Emetogenic Chemotherapy (HEC) over Multiple Cycles Dr. Rasna Gupta

New Patient Referral Form

In order to ensure your patient is triaged in the most efficient manner, please review the Disease Site Guidelines for required work-up scans and procedures.

It is expected that the referred patient has been informed of their diagnosis of cancer prior to their referral.

Cancer Centre clerical staff will contact new patients by telephone a few days after the referral is made to provide further information about their first appointment. This may cause undue stress for newly diagnosed patients if they are unaware of their diagnosis.

It is helpful to understand the distinction between referral types, and how New Patient Referral staff respond to each:

Standard Referral Seen within 2 weeks of referral Patients requiring consultation with a Medical or Radiation Oncologist for consideration of treatment options.
Urgent Referral Seen within 72 hours from time of referral Please call to discuss with the WRCP attending Oncologist. Patients who require immediate chemotherapy or radiation therapy to avoid potential oncological emergencies.
Emergency Referral Seen within 24 hours Please call to discuss with the WRCP attending Oncologist. Patients requiring immediate chemotherapy or radiation therapy for a life-threatening oncological emergency.

Diagnostic Assessment Programs (DAPs)

DAPs are designed to efficiently navigate patients with a suspicion of cancer to a definitive diagnosis. DAPs available in our region include Prostate and Lung.

If your patient meets the required referral criteria, please complete the referral form and fax it to 519-255-8688.

DAP Referral Form

Cancer Genetics Program

This program offers genetic counseling and testing for families at risk for inherited forms of cancer.

If you think that your patient’s personal and/or family history of cancer may be genetic, please complete the referral form and fax it to 519-255-8688.

Cancer Genetics Referral Form

Certain patients may be eligible for high risk screening programs based on genetic testing. Please refer to the OBSP section under the Cancer Screening Programs drop-down for more information.

Indigenous Navigator

The Indigenous Navigator helps indigenous patients, their families, and caregivers.

The Indigenous Navigator Can:

  • Provide your patient with support at clinic visits. 
  • Help your patient and their family communicate with Oncologists and Nurses. 
  • Arrange language and cultural translation. 
  • Help your patient find appropriate services. 
  • Connect your patient to a traditional knowledge keeper. 
If your patient would benefit from the Indigenous Navigators services listed above, please complete the referral form and fax it to 519-255-8670.

Indigenous Patient Referral Form

Palliative Care

Palliative care aims to improve the quality of life of patients who are diagnosed with life-limiting illnesses. This medical approach looks at each individual as a whole – physically, emotionally, psychologically, and spiritually.

Patients must be active patients, and meet all three criteria to be seen:

  • Life expectancy of less than 1 year. 
  • Malignant pain (if the pain is an issue). 
  • Patient must be aware of the referral. 

If your patient meets the required referral criteria, please complete the referral form and fax it to 519-255-8679.

Referral Form Coming Soon.

Hospice of Windsor Essex County

Criteria for Referral: Palliative Care Physician Consultation 

A diagnosis of life-threatening illness considered palliative requiring:

*** Please indicate the appropriate request on the referral form ***

  • End of Life Care – Prognosis Three Months or Less. 
  • Malignant Pain and Symptom Management – Consult Only. 
  • Non-Malignant End of Life Care – Consult/Share Care Only. 
Please Note:
  • For all End of Life referrals, the prognosis should already have been discussed.
  • Home visits are not intended to replace Primary Care responsibilities.
  • This program does not accept referrals for Chronic Non-Malignant Pain.
  • For Urgent Referrals: Call to speak to the Palliative Care Coordinator at Ext. 2254. Referrals are triaged at the time of receipt. Urgent faxes will not be accepted without telephone contact. 
If your patient meets the required referral criteria, please complete the referral form and send it to:

C/O The Hospice of Windsor Essex County Inc. 
6038 Empress Street, Windsor, Ontario N8T 1B5
Fax: 519-974-7672
Phone: 519-974-7100

Doctor's Referral Form to Palliative Medicine Physician Program

Cancer Care Ontario Resources


Diagnostic pathways 

Diagnosis and Treatment:

Pathways are a quality improvement tool for the Ontario cancer system. Pathways are flowcharts that show a high-level overview of the care a cancer patient in Ontario should receive.

The following pathways have been developed by Cancer Care Ontario to guide cancer treatment in the province:

Disease Pathway Maps - Healthcare Provider Q&A

Cancer Care Ontario Disease Pathway Management

Multidisciplinary Cancer Conferences (MCCs)

MCCs are regularly scheduled meetings where healthcare providers discuss the diagnosis and treatment of individual cancer patients. Participants represent medical oncology, radiation oncology, surgical oncology, pathology, diagnostic radiology, and nursing.

To submit a patient for review at an MCC, please complete the MCC Submission Form and submit to or fax to 519-255-8687.

Breast Reconstruction Booklet

Learn more about breast reconstruction options in this Breast Reconstruction Resource.

Survivorship Resources

Surveillance and Follow-up Guidelines

To request physical copies of the guides, call 519-254-5577 ext. 58620.

Survivorship - Information on Common Concerns

The Canadian Cancer Society highlights some common concerns that cancer survivors may face when thinking about the future:

Patient and Family Advisory Council / Patient & Family Advisor

Your input assists our Patient and Family Advisory Council (PFAC) in making lasting impact improvements for patients with cancer and their caregivers across the Erie St. Clair Region in the areas of prevention, screening, diagnosis, treatment, survivorship, palliative, and end-of-life care.

Council membership includes patients, family members and caregivers from the Chatham-Kent, Sarnia/Lambton and Windsor/Essex area. Membership also includes cancer program leadership and staff.

The Patient & Family Advisory Council meets four times per year. To acknowledge the significant partnership between the cancer program and patients/family/caregivers, meetings and outcomes are guided by the membership and are led by a Program Chair and Patient Chair.

For more information, please see the documents below, or contact our Call Centre at 519-253-5253.

The Patient & Family Advisor (PFA) is another opportunity to provide feedback to the Cancer Program. PFAs are able to determine their level of involvement with initiatives based on their interests. There are various sub-committees for members to choose to join and meetings are on an ad hoc basis until completion of the initiative. 

For more information, see the document below or contact our Call Centre at 519-253-5253.



The Erie St. Clair Regional Cancer Program Clinical Leads.

Lead Title
Dr. Youssef Almalki Cancer Imaging Lead, Breast Imaging Lead
Dr. Elizabeth Haddad Colorectal Screening / GI Endoscopy Lead
Dr. Tamara Siddall Primary Care Lead (Day 1 – Prevention, Screening, Diagnosis)
Dr. John Mathews Quality Lead, Systemic Treatment
Ms. Sarah Mushtaq Patient Education Lead
Dr. Raj Goel Surgical Oncology Lead
Ms. Priya Philip Psychosocial Oncology Lead
Dr. Ken Schneider Radiation Clinical Lead
Dr. Mohammad Alomari Pathology Lead
Vacant Indigenous Cancer Lead
Dr. Neerja Sharma Regional Coloscopy / Cervical Cancer Screening Lead
Ms. Priya Philip Co-Patient and Family Engagement and Experience Lead
Ms. Melissa Lot Oncology Nursing Lead
Dr. Glen Maddison Co-Regional Multidisciplinary Physician Lead,
Erie St. Clair Regional Hospice Palliative Care Network
Ms. Janet Elder Co-Regional Multidisciplinary Clinical Lead,
Erie St. Clair Regional Hospice Palliative Care Network

Cancer Centre Contact Information.